Genome profiler launches IPO


Paris – This year’s third small IPO went out on the Alternext market of Euronext Paris this year, with molecular diagnostics company IntegraGen S.A. raising EUR6.7m through the sale of 800,149 shares at a8.40, giving it a post-money valuation of EUR31.7m. Founded in 2000, IntegraGen is using its Genome Hybrid Identity Profiling approach to identify disease genes by analysing the shared genes among a small sample of family members with a given disease. The goal is to develop and distribute molecular diagnostics based on the identified markers. The company is focused on cancer and autism. In the oncology setting, IntegraGen recently signed a partnership with in vitro diagnostics specialists BioMerieux S.A. to create a molecular diagnostics laboratory within the Assistance Publique Hôpitaux de Paris. The main goal of this partnership is to validate biomarkers. With the proceeds from the IPO, IntegraGen says it plans to launch a pair of biomarker assays for hepato­cellular carcinoma and metastatic colorectal cancer by 2013. In addition, IntegraGen has identified eight SNPs associated with a doubled risk of autism.
Two other IPOs went on the Alternext in April. Autoimmune and inflammation company Neovacs S.A. raised EUR10m, while bioprocessing specialist Deinove S.A. brought in EUR12.1m.



Minneapolis/Banzancourt – Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale. The French/US enterprise has now scaled up its...



Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version...



Paris/Barcelona – French pharma company Sanofi strengthens its ties with the Spanish research institution CGR (Center for Genomic Regulation) in Barcelona. CGR stated on 12 March that the two partners agreed upon three years of...



Lyon – The sale of 1.6 million shares brought in €25.3m for French Adocia SAS during its IPO on the Euronext Paris. The price of €15.88 values the diabetes specialist at €96.1m at the upper end of the bookbuilding range. Late...



Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The...



Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased...



Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and...



Shares of the French diabetes specialist almost doubled when the companypublished results of its Phase II study with the PPAR alpha and deltamodulator GFT505. The compound has met the co-primary and secondaryendpoints while...



Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an...



Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of...

Displaying results 1 to 10 out of 268

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues